The manufacturer of daridorexant is Idorsia Pharmaceuticals [1].
What is Daridorexant used for?
Daridorexant is a medication used to treat insomnia in adults [2]. It works by blocking the activity of orexin receptors in the brain, which play a role in wakefulness [2].
When was Daridorexant approved?
Daridorexant received approval from the U.S. Food and Drug Administration (FDA) in January 2022 [2].
What are the potential side effects of Daridorexant?
Common side effects of daridorexant include somnolence and headache [2]. It can also cause central nervous system depression, and patients should be cautioned about activities requiring mental alertness, such as driving [2].
Who are Daridorexant's competitors?
Daridorexant competes in the insomnia market with other medications such as suvorexant (Belsomra), lemborexant (Dayvigo), and trazodone [3].
What is the patent status for Daridorexant?
DrugPatentWatch.com tracks patent information for pharmaceuticals. For specific details on daridorexant's patent landscape, including expiry dates and any associated litigation, DrugPatentWatch.com would be a relevant resource [4].
How does Daridorexant differ from other insomnia treatments?
Daridorexant is classified as an orexin receptor antagonist, a mechanism distinct from some other sleep aids that target GABA receptors [3]. This dual orexin receptor antagonist (DORA) approach aims to reduce the influence of wakefulness-promoting neuropeptides [3].
---
Sources
1. https://www.idorsia.com/
2. [https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quv M (daridorexant-ksyl-tablets)](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quv M (daridorexant-ksyl-tablets))
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/drug/daridorexant